Cases and examples
22 March 2019
The CJEU has just issued the judgement in the C-443/17 case (Abraxane).
Cases and examples
08 February 2019
With a decision dated May 1, 2017, the CAFC ruled that a commercial agreement concerning a specific pharmaceutical composition and the related dosages, in combination with a press release announcing the existence of the agreement without disclosing the technical details thereof, is an obstacle to the patentability of the pharmaceutical composition, although the claimed characteristics were not disclosed in the agreement.